Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AQST, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
AQST reported $98.5M in cash and short-term investments (as of Jun 30, 2026) and used about $12.2M/quarter in operations, an estimated runway of 24.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AQST files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 7,992,647 | 6.37% | 2026-06-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 6,250,000 | 4.98% | 2025-09-30 |
| Daniel Barber President and CEO, Director · +816,100 options |
Insider | 652,317 | 0.52% | 2026-09-15 |
| Peter E. Boyd Chief People Officer · +102,500 options |
Insider | 284,024 | 0.23% | 2026-09-09 |
| A Ernest Jr Toth Chief Financial Officer · +152,500 options |
Insider | 283,460 | 0.23% | 2026-05-05 |
| Melina Cioffi SVP, Regulatory Affairs · +75,000 options |
Insider | 273,200 | 0.22% | 2026-05-15 |
| Sherry Korczynski Chief Commercial Officer · +136,250 options |
Insider | 235,689 | 0.19% | 2026-09-09 |
| Lori J Braender Corporate Secretary · +132,500 options |
Insider | 231,042 | 0.18% | 2026-05-07 |
| Cassie Jung Chief Operating Officer · +102,500 options |
Insider | 208,833 | 0.17% | 2026-09-03 |
| Thomas A. Zalewski Chief Legal Officer · +75,000 options |
Insider | 100,000 | 0.08% | 2026-05-18 |
| John Cochran Director · +50,500 options |
Insider | 99,486 | 0.08% | 2026-06-10 |
| Gregory B Brown Director · +50,500 options |
Insider | 75,085 | 0.06% | 2026-06-10 |
Share count 125,511,648 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-01-31 | Anaphylm | NDA | -53.8% | +39% | +39.3% |
| 2025-11-06 | — | NDA | +0.5% | +2.2% | -7% |
| 2025-10-08 | Anaphylm | NDA | +19.2% | +3.9% | +15.2% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AQST and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →